Revaprazan

DB16308InvestigationalSmall molecule

Revaprazan is under investigation in clinical trial NCT01750437 (Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(nerd)).

Mechanism: Pharmacologically active on Potassium-transporting ATPase alpha chain 1
Curator reviewed
Formula / weight: C₂₂H₂₃FN₄ · 362.452 g/mol (avg)
Also known as: Yh-1885 free base
Code names: SB-641257

Resolves to

Compound

UNII5P184180P5CAS199463-33-7ChEMBLCHEMBL1618279ChEBI135529

Structure

InChIKeyLECZXZOBEZITCL-UHFFFAOYSA-NSMILESCC1N(CCC2=C1C=CC=C2)C1=NC(NC2=CC=C(F)C=C2)=NC(C)=C1C

Targets

P20648ATP4AQ13639HTR4

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Revaprazan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account